Abstract: TH-PO0521
Clinical Investigation of the Novel MultiFlux Hemofilter in CKRT Treatments Using Systemic Heparin or Regional Citrate Anticoagulation
Session Information
- Dialysis: Novel Therapeutics and Medication Management
November 06, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Dialysis
- 801 Dialysis: Hemodialysis and Frequent Dialysis
Authors
- Meyer, Celina, Fresenius Medical Care Deutschland GmbH, Bad Homburg, HE, Germany
- Gillen, Christine, Fresenius Medical Care Adsorber Tec GmbH, Krems an der Donau, Lower Austria, Austria
- Herrmann, Anja, Fresenius Medical Care Deutschland GmbH, Bad Homburg, HE, Germany
- Theis, Lukas, Fresenius Medical Care Deutschland GmbH, Bad Homburg, HE, Germany
- Zawada, Adam M., Fresenius Medical Care Deutschland GmbH, Bad Homburg, HE, Germany
- Derlet-Savoia, Anja, Fresenius Medical Care Deutschland GmbH, Bad Homburg, HE, Germany
- Stauss-Grabo, Manuela, Fresenius Medical Care Deutschland GmbH, Bad Homburg, HE, Germany
Background
Continuous kidney replacement therapy (CKRT) is essential for acutely ill patients experiencing life-threatening fluid, electrolyte, and acid-base imbalances, such as severe hyperkalemia, acidosis, pulmonary edema, or uremic complications. The core element for such treatments is the hemofilter, which plays a key role in treatment efficiency. Although most modern, high-flux dialyzers use synthetic membranes based on e.g. polysulfone (PS), polyethersulfone (PES), or polyarylethersulfone (PAES), differences in material composition, manufacturing as well as membrane morphology, structure and adsorptive properties mainly determine dialyzer performance and hemocompatibility. The novel multiFlux hemofilter uses a hydrophilic membrane previously shown to reduce membrane fouling linked with sustained performance and improved hemocompatibility. The present clinical study will investigate this novel hemofilter among patients with acute kidney injury (AKI) using systemic anticoagulation with unfractionated heparin and regional citrate anticoagulation (RCA).
Methods
This study is a prospective, open, interventional, multicenter, international study focusing on extracorporeal blood purification with multiFlux hemofilters (developed by Fresenius Medical Care, Bad Homburg) during CKRT with RCA using 4% citrate or systemic heparin anticoagulation. In total, 40 AKI patients with a body weight over 8 kg will be included and treated for up to 7 days based on physician's decision. The study aims to assess performance (clearance of urea and creatinine, correction of acid-base status and electrolyte imbalances), safety (adverse events, including hemodynamic instability or bleeding) as well as the life span of the dialyzer across treatments.
Results
Our Study is designed to assess the performance of the novel multiFlux hemofilter during CKRT. The study results are planned to be published in 2027.
Conclusion
This study aims to extend knowledge on extracorporeal blood purification with multiFlux hemofilters during CKRT using either RCA or systemic heparin anticoagulation for patients suffering from AKI. The results will also help to understand whether hydrophilic membrane modification may improve performance stability and filter life span during CKRT.
Funding
- Commercial Support – Fresenius Medical Care